Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression.
about
Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association studyCancer pharmacogenomics: strategies and challengesGlutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapyPharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspectiveIn vitro human cell line models to predict clinical response to anticancer drugsTurning off AKT: PHLPP as a drug targetCytosolic 5'-nucleotidase III (NT5C3): gene sequence variation and functional genomicsPharmacogenomic discovery using cell-based modelsGemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkersSelf-contained gene-set analysis of expression data: an evaluation of existing and novel methodsFKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of pancreatic cancerSystematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsinAnalysis of genome-wide RNA-sequencing data suggests age of the CEPH/Utah (CEU) lymphoblastoid cell lines systematically biases gene expression profiles.Pharmacogenomics: candidate gene identification, functional validation and mechanisms.Copy number variation and cytidine analogue cytotoxicity: a genome-wide association approach.Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes.Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell linesCD38 expression, function, and gene resequencing in a human lymphoblastoid cell line-based model systemPharmacogenomics: a systems approach.Genetic association studies of copy-number variation: should assignment of copy number states precede testing?Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell linesHeritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines.Simultaneous analysis of multiple data types in pharmacogenomic studies using weighted sparse canonical correlation analysisEcto-5'-nucleotidase and thiopurine cellular circulation: association with cytotoxicity.Identifying the genetic variation of gene expression using gene sets: application of novel gene Set eQTL approach to PharmGKB and KEGG.Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study.Lung cancer signature biomarkers: tissue specific semantic similarity based clustering of digital differential display (DDD) data.Acetaminophen-NAPQI hepatotoxicity: a cell line model system genome-wide association study.Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.Multivariate models to detect genomic signatures for a class of drugs: application to thiopurines pharmacogenomics.Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinomaIdentification of genetic variants or genes that are associated with Homoharringtonine (HHT) response through a genome-wide association study in human lymphoblastoid cell lines (LCLs)Clinical pharmacology and pharmacogenetics of gemcitabine.Cardiovascular pharmacogenomics and individualized drug therapyLymphoblastoid cell lines models of drug response: successes and lessons from this pharmacogenomic model.Mycophenolic acid response biomarkers: a cell line model system-based genome-wide screen.Gemcitabine Cytotoxicity: Interaction of Efflux and Deamination.Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy.Impact of genetic variation in FKBP5 on clinical response in pediatric acute myeloid leukemia patients: a pilot study.Molecular insight into thiopurine resistance: transcriptomic signature in lymphoblastoid cell lines.
P2860
Q21261276-3EA2A76C-7DC0-44DE-90AB-FABCFAF497C3Q24289309-86755DDC-E9BB-4A1D-9142-E7839150FCC7Q24629542-DAD5853A-B1C5-4B53-AB06-9F71B36433A1Q26752368-441D6889-FD97-4CDA-828F-60B546D9F56EQ27000665-5BEDA992-7C79-4B33-8938-32281E6AF48BQ27014094-F895752B-24E8-493B-B24C-402D8F40CC69Q28252663-D9D14C45-0E42-414F-887A-523B3100C074Q28392982-14F6F63D-2976-4CC8-978A-6F8B9BF1D078Q28471821-30DF6A2B-D12C-4E4B-B67B-10281382D0A0Q28475530-2908CFEF-0C3F-4A99-B111-45212845C142Q28483623-D3F3FBCB-C54E-4901-9B4C-A907541D20F0Q28817780-957AB3DE-C8BC-430C-8FBC-8476C0D3FBE3Q30885478-791398B8-20D4-4E68-A77A-69713D0C136AQ33375573-11CDDD60-012C-420C-A666-86AD14906090Q33595261-0AA6D8D1-31C3-4CD4-96DA-601B76E3CB96Q33637143-D8E1FF94-8C05-4988-92E5-3E6EF3F29A05Q33746404-FC8BC7FB-C264-4163-BB3E-A3CC146FBB5CQ33940572-C40EEE44-A371-4902-B02E-226E5D0804AAQ34137575-A72EBEDC-FAD8-48AF-B645-0ED5FF2FC58CQ34228348-559EC7E7-C92D-4CA5-9474-A30D2C8613C0Q34239148-D368B848-0AA5-48CB-8D3A-4E03E7E3AA50Q34288272-6E9E8E75-FC8E-4E4D-A4CB-E4F22E64C97EQ34317474-821934E3-008B-4F84-B184-40A5F90F527AQ34359524-AA5CCE97-AE33-4085-A7B4-FE631EF11DF0Q34384986-DD10CFCB-301A-4719-84BA-7AA371FC4E03Q34459766-76A484CC-1310-4F13-AEF4-99BEB835755FQ34466055-C0AC3011-E9C6-401D-A582-95F255C10B4EQ34601408-0E84F6E1-B971-4566-93F3-99095D8125AEQ34789161-CE459078-0C63-4928-9CCF-24F973A10847Q34883498-068E53D1-BB04-4FA0-A690-7187B97A8A7DQ34925232-FB44D33D-CFF6-49D0-B978-F7C884BC0213Q34937030-34AE0EBC-D2C7-4DDA-A617-C9EF4DCB3A7FQ34985979-E9ECD334-AEF1-4FF0-B5A9-BFC259136CC2Q35025518-489414FF-7F42-4078-89B8-D8D7DFAA0104Q35068272-FC3FD82E-1C92-49DC-87A6-EBEC93B17AD8Q35112606-42DDE2E7-C305-469C-84E8-C686EC84FAA0Q35130652-C72BEA8E-7720-443C-AD08-585D21FB86B4Q35196480-7DC8667E-F496-4EAA-A3FF-2A49FB12E405Q35615051-38E499A2-F8AE-4972-AD84-9D57BB1A45DFQ35646066-56513B86-A2A6-49F7-8038-90CBEDC4411C
P2860
Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Gemcitabine and cytosine arabi ...... ymphoblastoid cell expression.
@en
type
label
Gemcitabine and cytosine arabi ...... ymphoblastoid cell expression.
@en
prefLabel
Gemcitabine and cytosine arabi ...... ymphoblastoid cell expression.
@en
P2093
P2860
P1433
P1476
Gemcitabine and cytosine arabi ...... ymphoblastoid cell expression.
@en
P2093
Brooke Fridley
Daniel Schaid
Gregory Jenkins
Krishna Kalari
Liewei Wang
Matthew Ames
Michelle Hildebrandt
Stephanie Safgren
P2860
P304
P356
10.1158/0008-5472.CAN-08-0405
P407
P577
2008-09-01T00:00:00Z